ES8802439A1 - Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa). - Google Patents

Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa).

Info

Publication number
ES8802439A1
ES8802439A1 ES557374A ES557374A ES8802439A1 ES 8802439 A1 ES8802439 A1 ES 8802439A1 ES 557374 A ES557374 A ES 557374A ES 557374 A ES557374 A ES 557374A ES 8802439 A1 ES8802439 A1 ES 8802439A1
Authority
ES
Spain
Prior art keywords
hydrochloride salt
solid hydrochloride
solid
preparation
aqueous solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES557374A
Other languages
English (en)
Other versions
ES557374A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB858513358A external-priority patent/GB8513358D0/en
Priority claimed from GB858521705A external-priority patent/GB8521705D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Publication of ES8802439A1 publication Critical patent/ES8802439A1/es
Publication of ES557374A0 publication Critical patent/ES557374A0/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

METODO DE PREPARACION DE UNA SAL FISIOLOGICAMENTE ACEPTABLE DE ACTIVADOR DE PLASMINOGENO DE TEJIDO (T-PA). SE SECA, A UNA PRESION ENTRE 0.01 TORR Y 0.1 TORR, UNA SOLUCION ACUOSA CONGELADA DE UNA SAL T-PA QUE TIENE UN PH DE 2 A 5, SIENDO LA TEMPERATURA INICIAL DE -30 A -40 GC Y LA TEMPERATURA FINAL IGUAL O SUPERIOR A LA AMBIENTE DESPUES DE QUE SE HAYA SUSTANCIALMENTE TODA EL AGUA. LA SAL ES UNA SAL DE ADICION DE ACIDO FISIOLOGICAMENTE ACEPTABLE DE T-PA, O UNA SAL HIDROCLORURO DE T-PA. DE APLICACION EN MEDICINA HUMANA Y VETERINARIA.
ES557374A 1985-05-28 1987-02-10 Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa). Expired ES8802439A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858513358A GB8513358D0 (en) 1985-05-28 1985-05-28 Formulation
GB858521705A GB8521705D0 (en) 1985-08-31 1985-08-31 Formulation

Publications (2)

Publication Number Publication Date
ES8802439A1 true ES8802439A1 (es) 1988-06-01
ES557374A0 ES557374A0 (es) 1988-06-01

Family

ID=26289290

Family Applications (2)

Application Number Title Priority Date Filing Date
ES555353A Expired ES8800601A1 (es) 1985-05-28 1986-05-27 Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)
ES557374A Expired ES8802439A1 (es) 1985-05-28 1987-02-10 Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES555353A Expired ES8800601A1 (es) 1985-05-28 1986-05-27 Un procedimiento para preparar una formulacion farmaceutica liofilizada de activador de plasminogeno de tejidro (t-pa)

Country Status (22)

Country Link
US (2) US4929444A (es)
JP (1) JPH0759517B2 (es)
AU (1) AU567236B2 (es)
BE (1) BE904830A (es)
CA (1) CA1300008C (es)
CH (1) CH665356A5 (es)
DE (1) DE3617752A1 (es)
DK (1) DK163173C (es)
ES (2) ES8800601A1 (es)
FI (1) FI85335C (es)
FR (1) FR2583984B1 (es)
GB (1) GB2176702B (es)
GR (1) GR861366B (es)
HU (1) HU195733B (es)
IL (1) IL78938A (es)
IT (1) IT1191926B (es)
LU (1) LU86444A1 (es)
NL (1) NL8601355A (es)
NO (1) NO171345C (es)
NZ (1) NZ216307A (es)
PT (1) PT82646B (es)
SE (1) SE462016B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8601354A (nl) * 1985-05-28 1986-12-16 Wellcome Found Nieuwe samenstelling.
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
US5034225A (en) * 1985-12-17 1991-07-23 Genentech Inc. Stabilized human tissue plasminogen activator compositions
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
US4976959A (en) * 1986-05-12 1990-12-11 Burroughs Wellcome Co. T-PA and SOD in limiting tissue damage
BE1001425A4 (fr) * 1986-05-12 1989-10-31 Wellcome Found Utilisation de l'activateur tissulaire du plasminogene, son association avec une superoxyde-dismutase et formulation pharmaceutique contenant cette association.
GB8619098D0 (en) * 1986-08-05 1986-09-17 Wellcome Found Combination
US5270198A (en) * 1988-05-20 1993-12-14 Genentech, Inc. DNA molecules encoding variants of tissue plasminogen activators, vectors, and host cells
US5342616A (en) * 1988-06-20 1994-08-30 The Wellcome Foundation Limited Method of administering tissue plasminogen activator
US5262170A (en) * 1988-09-02 1993-11-16 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties and substituted at amino acid positions 296-299, DNA molecules encoding them, vectors, and host cells
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
DE3835350A1 (de) * 1988-10-17 1990-04-19 Boehringer Mannheim Gmbh Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
DE3942142A1 (de) * 1989-12-20 1991-06-27 Boehringer Mannheim Gmbh Stabilisierung von glykosyliertem t-pa
WO1992011866A1 (en) * 1991-01-14 1992-07-23 Duke University LAMININ SEQUENCE AS tPA ACTIVATOR
JP3559559B2 (ja) * 1992-06-03 2004-09-02 ジェネンテク，インコーポレイテッド 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体
ES2206602T3 (es) * 1995-10-23 2004-05-16 The Children's Medical Center Corporation Compuestos y metodos terapeuticos inhibidores de angiogenesis.
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
KR100477280B1 (ko) * 1995-12-13 2005-07-18 아보트 러보러터리즈 맥관형성에의한질환치료제
EP0827751B1 (en) * 1996-09-06 2003-02-26 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Medicinal composition containing tissue plasminogen activator and nicotinamide
US20030077682A1 (en) * 2001-09-07 2003-04-24 Hung Paul Porwen Human tissue urokinase type plasminogen activator formulation
US20040091465A1 (en) * 2002-06-26 2004-05-13 Zachary Yim Therapeutic antiangiogenic compositions and methods
US7670810B2 (en) * 2003-06-20 2010-03-02 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
US7491263B2 (en) * 2004-04-05 2009-02-17 Technology Innovation, Llc Storage assembly
AU2006236150A1 (en) * 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998947A (en) * 1973-11-30 1976-12-21 Pierre Fabre S.A. Process for obtaining a plasminogen activator
FR2252842B1 (es) * 1973-12-03 1977-11-04 Fabre Sa Pierre
DE3015699C2 (de) * 1979-04-26 1982-07-15 Asahi Kasei Kogyo K.K., Osaka Herstellung eines Plasminogen-Aktivators
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
JPS5951220A (ja) * 1982-08-02 1984-03-24 Asahi Chem Ind Co Ltd 新規なプラスミノ−ゲン・アクチベ−タ−およびその製法ならびにこれを含有する薬剤
NL191755C (nl) * 1982-10-29 1996-07-02 Mitsui Toatsu Chemicals Plasminogeenactivator en trombolytisch middel.
AU554862B2 (en) * 1982-12-14 1986-09-04 Implico B.V. Plasminogen activator isolated by affinity chromatography
NZ206699A (en) * 1982-12-30 1989-08-29 Bio Response Inc Process for the production of serum independent cell lines
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
EP0156169B1 (en) * 1984-02-29 1991-12-18 Asahi Kasei Kogyo Kabushiki Kaisha An aqueous solution of a tissue plasminogen activator dissolved therein at an increased concentration and a method
DE3439980A1 (de) * 1984-11-02 1986-05-07 Behringwerke Ag, 3550 Marburg Verfahren zur reinigung sowie pasteurisierung von urokinase
EP0201153A3 (en) * 1985-02-09 1987-10-07 Beecham Group Plc Modified enzyme and process for its preparation
GB8513358D0 (en) * 1985-05-28 1985-07-03 Wellcome Found Formulation
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法

Also Published As

Publication number Publication date
FI85335C (fi) 1992-04-10
GB8612780D0 (en) 1986-07-02
CA1300008C (en) 1992-05-05
NL8601355A (nl) 1986-12-16
DK163173B (da) 1992-02-03
BE904830A (fr) 1986-11-27
GB2176702A (en) 1987-01-07
NZ216307A (en) 1989-10-27
FI862227A0 (fi) 1986-05-27
SE8602405L (sv) 1986-11-29
HUT41638A (en) 1987-05-28
JPH0759517B2 (ja) 1995-06-28
IT1191926B (it) 1988-03-31
IT8648065A0 (it) 1986-05-27
FR2583984A1 (fr) 1987-01-02
GB2176702B (en) 1989-07-05
NO171345B (no) 1992-11-23
ES555353A0 (es) 1987-11-16
NO862096L (no) 1986-12-01
IL78938A (en) 1993-02-21
PT82646B (pt) 1989-01-30
DE3617752A1 (de) 1986-12-04
DK246786D0 (da) 1986-05-27
US4929444A (en) 1990-05-29
HU195733B (en) 1988-07-28
ES8800601A1 (es) 1987-11-16
CH665356A5 (de) 1988-05-13
FI85335B (fi) 1991-12-31
LU86444A1 (fr) 1986-12-05
NO171345C (no) 1993-03-03
GR861366B (en) 1986-09-29
US4968617A (en) 1990-11-06
DE3617752C2 (es) 1988-06-30
FR2583984B1 (fr) 1989-06-02
DK246786A (da) 1986-11-29
SE462016B (sv) 1990-04-30
AU567236B2 (en) 1987-11-12
IL78938A0 (en) 1986-09-30
FI862227A (fi) 1986-11-29
SE8602405D0 (sv) 1986-05-27
PT82646A (en) 1986-06-01
AU5796486A (en) 1986-12-04
ES557374A0 (es) 1988-06-01
DK163173C (da) 1992-06-22
JPH06183995A (ja) 1994-07-05

Similar Documents

Publication Publication Date Title
ES8802439A1 (es) Un procedimiento para preparar una sal fisiologicamente aceptable de activador de plasminogeno de tejido (t-pa).
UA34419C2 (uk) Ліофілізований препарат для ін'єкцій та спосіб інгібування росту пухлин
ES8706443A1 (es) Un procedimiento para preparar una solucion parenteral de activador de plasminogeno de tejido (t-pa)
EP0233013A3 (en) Modified enzyme
HUT40804A (en) Process for production of medical preparatives containing n-acetyl neuramin acid
DE3650358D1 (de) Diphosphonate enthaltende pharmazeutische Zusammensetzungen zur Behandlung von Arthrosis.
IE863381L (en) Antibiotics
ES8303086A1 (es) "un metodo para producir una forma de farmaco para administracion no parenteral a base de l-piroglutamil-l-histidil-l-prolinamida."
ES2037136T3 (es) Procedimiento para la preparacion de una solucion con elevada actividad volumetrica de una proteina con actividad de activador de plasminogeno de tejidos (t-pa).
TW337997B (en) Pharmaceutical preparation containing plasminogen activators
NZ219829A (en) Tissue-type plasminogen activator modified in the region of amino acids 67-69 and pharmaceutical compositions thereof
HU908361D0 (en) Process for the production of oxazole derivatives and medical preparations containing them as active agents
HUT42102A (en) Process for preparing peptides with pharmaceutical activity
GB2234973B (en) Aqueous liquid enzyme formulation of proteolytically active enzymes
EP0228625A3 (en) Peptide derivatives inhibitors of hydroxyling enzymes, their process of preparation, the agents thereof and their use
HU893631D0 (en) Process for producing 1,1-dioxo-cephem-4-carbothiolic acid derivatives and pharmaceutical prepartives containing them as active substance
HUT44770A (en) Process for producing 6-phenoxymethyl-4-hydroxy-tetrahydropyran-2-one derivatives and pharmaceutical preparations comprising them as active substance
HUT59610A (en) Process for producing pharmaceutical compositions for solving blood clot containing t-pa without glycosilyzing
IL59724A0 (en) Pentadecapeptide and its salts,their preparation and pharmaceutical compositions containing them
ES8801624A1 (es) Procedimiento para preparar disulfuros heterociclicos
BG60542B2 (en) Water soluble composition having coccidiostatic effect
IL83495A0 (en) Oxirane pseudooligosaccharides,a process for their preparation,and pharmaceutical preparations containing them
GB1246727A (en) Therapeutic hypotensive compositions comprising 5-alkylpicolinic acids
ES8705847A1 (es) Procedimiento para preparar nuevos derivados de n-(2-hidro- xialquil)-aminoacidos
GB1386927A (en) Preparations for combatting swine dysentery

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970612